Materialise Reports Strong Q4 2025 Profitability Turnaround and Improved Cash Position

summarizeSummary

Materialise NV announced its Q4 and full-year 2025 financial results, highlighting a significant improvement in Q4 operating and net profit, alongside a stronger net cash position, driven by robust performance in its Medical segment.

check_boxKey Events

• Strong Q4 Profitability Rebound

  The company reported a Q4 2025 operating result of 3,111 kEUR, a significant improvement from a (1,268) kEUR loss in Q4 2024. Net profit for the quarter more than doubled to 6,206 kEUR from 2,907 kEUR in the prior year period.

• Adjusted EBITDA Surges in Q4

  Adjusted EBITDA for the fourth quarter of 2025 increased substantially to 9,524 kEUR, up from 4,306 kEUR in Q4 2024, indicating improved operational efficiency.

• Medical Segment Drives Growth

  The Materialise Medical segment showed robust performance, with Q4 2025 revenue increasing by 16.3% and full-year revenue growing by 15.4%, alongside improved Adjusted EBITDA margins.

• Improved Net Cash Position

  Materialise NV ended 2025 with 133,918 kEUR in cash and cash equivalents, resulting in a net cash position of 70,805 kEUR, an increase of 9,785 kEUR compared to December 31, 2024.

auto_awesomeAnalysis

Materialise NV's Q4 2025 results demonstrate a significant rebound in profitability, with operating profit swinging from a loss to a gain and net profit more than doubling year-over-year. This strong quarterly performance, particularly in the Materialise Medical segment, contributed to an improved net cash position. While full-year net profit declined, the company attributed this primarily to unfavorable exchange rate fluctuations, and full-year Adjusted EBITDA still saw a modest increase. The continued growth and strong margins in the Medical segment are key drivers, offsetting declines and unprofitability in the Manufacturing segment.